Contents hide 1 Approval in Japan 2 Non-small Cell Lung Cancer 3 Dosage Modifications 3.1 Dose reduction schedule Alectinib is a type of cancer growth blocker called a tyrosine kinase inhibitor. It works by blocking certain chemical messengers that tell cells to grow. This stops or slows down the cancer. Approval in Japan Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma . Non-small Cell Lung Cancer Indicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test 600 mg PO BID until disease progression or unacceptable toxicity See Administration … Continue reading Alynni (Alectinib)